l General Information |
Product Name | Doxorubicin HCl |
General description | Doxorubicin Hydrochloride is an anthracycline antibiotic with antineoplastic activity. |
Synonym | (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; hydrochloride; 盐酸多柔比星;AdriaMycin HCl; |
Purity | ≥98%(HPLC) | CAS Number | 25316-40-9 |
Formula | C27H29NO11·HCl | Molecular Weight | 579.983 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Orange-red solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Very slightly soluble |
Water | ≥15mg/mL |
l Biological Information |
Biochem/Physiol Actions | Doxorubicin Hydrochloride is the hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA ed complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects. |
Application | 1.Antibiotics, Antineoplastic 2.Topoisomerase II Inhibitors |
l Packaging & Storage |
Packaging | 50mg; 250mg; 1g |
Storage temp. | -5-0℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
